The recent trial of antisense oligonucleotide treatment with Sepofarsen for RPE65 mutation-associated retinal dystrophy has demonstrated risks such as cataractogenesis, retinal thinning, and cystoid macular changes [18]. Here, RPE65 is linked to Retinal dystrophy.